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ABSTRACT
Objective: To assess effectiveness and
implementability of the public health programme Life!
Taking action on diabetes in Australian people at risk of
developing type 2 diabetes.
Research design and methods: Melbourne
Diabetes Prevention Study (MDPS) was a unique study
assessing effectiveness of Life! that used a randomized
controlled trial design. Intervention participants with
AUSDRISK score ≥15 received 1 individual and 5
structured 90 min group sessions. Controls received
usual care. Outcome measures were obtained for all
participants at baseline and 12 months and,
additionally, for intervention participants at 3 months.
Per protocol set (PPS) and intention to treat (ITT)
analyses were performed.
Results: PPS analyses were considered more
informative from our study. In PPS analyses,
intervention participants significantly improved in
weight (−1.13 kg, p=0.016), waist circumference
(−1.35 cm, p=0.044), systolic (−5.2 mm Hg, p=0.028)
and diastolic blood pressure (−3.2 mm Hg, p=0.030)
compared with controls. Based on observed weight
change, estimated risk of developing diabetes reduced
by 9.6% in the intervention and increased by 3.3% in
control participants. Absolute 5-year cardiovascular
disease (CVD) risk reduced significantly for
intervention participants by 0.97 percentage points
from 9.35% (10.4% relative risk reduction). In control
participants, the risk increased by 0.11 percentage
points (1.3% relative risk increase). The net effect for
the change in CVD risk was −1.08 percentage points
of absolute risk (p=0.013).
Conclusions: MDPS effectively reduced the risk of
diabetes and CVD, but the intervention effect on weight
and waist reduction was modest due to the challenges
in recruiting high-risk individuals and the abbreviated
intervention.
Recent assessments indicate that 8.3% of
adults worldwide (382 million people) have
diabetes, and total numbers are projected to
exceed 592 million within 25 years.1 Effective
prevention is critical to reduce this looming
burden of disease. In the randomized con-
trolled setting, efﬁcacy has been shown for
lifestyle interventions, with progression to
type 2 diabetes mellitus (T2DM) reduced by
up to 58%,2–4 and with beneﬁcial effects
evident at 13 years follow-up.5 Guidelines
have been produced and a systematic review
Key messages
▪ Questionnaires are an inexpensive and rapid way
to screen for people at risk of diabetes and to
raise awareness of an individual’s risk.
▪ The threshold criterion used for an Australian
questionnaire, AUSDRISK, resulted in recruit-
ment of participants at very low risk of progres-
sion to diabetes or cardiovascular disease.
▪ For entry to diabetes prevention programmes,
the use of questionnaires should be combined
with measurement of impaired fasting glucose,
impaired glucose tolerance, or glycosylated
hemoglobin.
Research questions
▪ Knowledge about cost-effectiveness of interven-
tions to prevent progression to diabetes is
limited. What should be the questionnaire cut-off
points for screening by clinical tests for entry to
interventions that would give best value for
money?
▪ How can implementation in the real world be
improved to maintain the effects of interventions
observed under trial conditions?
▪ How could quality improvement techniques be
used to improve the effectiveness of diabetes
prevention interventions in the real world?
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has identiﬁed 22 small-scale, real-world translational dia-
betes prevention programmes.6–8 Little is known about
their cost-effectiveness or their impact on cardiovascular
disease (CVD), the main cause of morbidity and mortal-
ity in diabetes.6 Only two scaled-up programmes have
been reported to date: FIN D2D9 and Life! Taking action
on diabetes (Life!).10
Life! is a statewide, group-based, lifestyle modiﬁcation
programme, targeting people at high risk of developing
T2DM in Victoria, Australia.10 Funded by the Victorian
Government Department of Health and coordinated by
Diabetes Australia—Victoria, it was modiﬁed in 2012 to
Life! Helping you prevent diabetes, heart disease and stroke,
with revised inclusion criteria and further programme
development to speciﬁcally include CVD prevention
(see online supplementary ﬁle 1). Approximately 25 000
people have participated in the Life! programme since
2007. The ﬁve programme goals, targeting improved
diet and physical activity, are from the Finnish Diabetes
Prevention Study (FIN DPS).4 The system design is
drawn from the Good Ageing in Lahti (GOAL) implemen-
tation trial,11 and is a scaled-up version of the Greater
Green Triangle Diabetes Prevention Project (GGT
DPP), an Australian Government-funded national dem-
onstrator project.12 During 2009–2014 the Melbourne
Diabetes Prevention Study (MDPS) evaluated the effect-
iveness of the Life! programme. The objective was to
learn from its results in order to further improve the
programme and to describe the challenges of real-world
diabetes prevention. Using a randomized controlled trial
(RCT) for evaluation of a scaled-up, real-world diabetes
prevention programme is unique.
Efﬁcacy studies emphasize internal validity and ask
‘Can it work?’, excluding real-world factors, so the inter-
vention alone is measured. Effectiveness studies ask
‘Does it work?’ in the real world, thus providing some
indication of external validity and generalizability.13–15
Scaling-up refers to widespread adoption of interven-
tions among real-world populations that retain or
improve their effectiveness, affordability, and sustainabil-
ity. Because of external, real-world factors, policies based
on apparently sound evidence from RCTs may lead to
implementation strategies that can encounter practical
problems when scaled-up within complex health
systems.16
The challenge now is to translate the positive out-
comes from efﬁcacy trials into effective real-world dia-
betes prevention programmes. Since there is little
experience in how to translate such programmes, we
also drew on emerging methodologies, like the Dynamic
Sustainability Framework (DSF), which provided a guide
for implementation.17 We apply the concepts of pro-
gramme drift and voltage drop from the DSF when
reporting the results of the MDPS to categorize the
lessons from scaling-up to a statewide programme for
which sustainability is also relevant. Our aim is that
other countries can learn from our experience when
they implement their own large-scale programmes.
RESEARCH DESIGN AND METHODS
The trial protocol, outlined brieﬂy below, has been pub-
lished elsewhere.18
Study design
MDPS was a unique prospective parallel group RCT to
assess the effectiveness of the Life! programme imple-
mented in Victoria, Australia, for people 50–75 years old
at risk of developing T2DM (note the Life! inclusion cri-
teria, including age, evolved over the period of the
RCT). Over 8 months, intervention participants received
a diabetes prevention programme and controls received
usual care from their general practitioners (GPs).
Online supplementary ﬁle 2 shows the CONSORT
diagram.
Recruitment
Eastern Melbourne metropolitan participants were
recruited from general practices, accredited Life! pro-
vider organizations, pharmacies, community organiza-
tions, and events. To maximize recruitment and
retention, multiple modes of participant contact were
collected and used to engage participants. Developing a
social connection with participants was important. The
same nurse was responsible for all participant contacts
and testing during the study.
Eligibility
Individuals scoring ≥15 on AUSDRISK aged 50–75 years
were eligible.19 A score of 15–19 represents a
one-in-seven risk of developing diabetes in 5 years, and
scores of ≥20 a one-in-three risk. Exclusion criteria were:
existing diabetes, laboratory evidence of existing T2DM
deﬁned as having a 2 h oral glucose tolerance test
(OGTT) result of ≥11.1 mmol/L and/or a fasting
plasma glucose (FPG) ≥7 mmol/L, severe mental
illness, substance abuse, myocardial infarction within
previous 3 months, pregnancy, difﬁculty with English,
and other household members already involved in the
study.
Randomization
Randomization occurred after eligibility was conﬁrmed
at baseline testing, described below. Individuals who
were found to already have T2DM at baseline were
excluded (FPG ≥7 mmol/L and/or 2 h glucose
≥11.1 mmol/L on OGTT). Randomization occurred
using a sealed-envelope system, containing randomiza-
tions sourced from a random number table allocating
participants to study arms in a 1:1 ratio.
Intervention
The intervention consisted of an initial 30–45 min indi-
vidual session followed by ﬁve structured 90 min group
sessions. The goals were: ≤30% energy from fat; ≤10%
energy from saturated fat; ≥15 g/1000 kcal ﬁber;
≥30 min/day moderate-intensity physical activity; and
≥5% body weight reduction.4 Lifestyle change processes
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and detailed goals were individually tailored using
problem-solving and goal-setting approaches. Trained
MDPS facilitators (backgrounds in psychology, nutri-
tion/dietetics and nursing) delivered all intervention
sessions. The individual session was designed to maxi-
mize participant retention, increase personal risk
awareness, undertake goal setting, and motivate change.
Four group sessions followed at two-week intervals (gen-
erally 8–15 participants per group) and the ﬁnal ﬁfth
session occurred 8 months after the initial group session
(ﬁgure 1). Control participants were told of their high
risk but continued with usual care from their GPs.
The intervention followed the Health Action Process
Approach framework.20–22 Facilitators moderated discus-
sions on problem solving and goal setting, provided
feedback, and strengthened the groups’ social support
role. Feedback on participant outcome measures was
provided after testing at 3 months (see below) and was
used to highlight intervention impact and sustain partici-
pants’ motivation for lifestyle change.
Anthropometric measurements and laboratory testing
Anthropometric measurements followed international
recommendations: WHO’s Multinational MONItoring of
Trends and Determinants in CArdiovascular Disease
(MONICA) protocol and current European Health Risk
Monitoring project.23 24 Both groups underwent
anthropometric and laboratory tests at baseline (T1)
and 12 months (T3; weight, waist circumference, blood
pressure (BP), fasting triglycerides, total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipo-
protein (HDL) cholesterol, FPG, 2 h OGTT glucose, gly-
cated hemoglobin). Intervention participants
additionally underwent these tests, except OGTT, at
3 months (T2; ﬁgure 1). All anthropometric measure-
ments were performed by trained nurses using the same
equipment at all time points. Laboratory analyses were
performed by Melbourne Pathology (NATA accredited
with CDC traceable standardization). Participants self-
reported dietary intake at T1 and T3 (Food Frequency
Questionnaire, FFQ),25 and physical activity at T1, T2
and T3 (Active Australia questionnaire).26
Outcome assessments
Primary outcomes were estimated changes in risk of pro-
gression to diabetes and CVD determined from changes
in weight, waist circumference, FPG, 2 h glucose on the
OGTT, BP, and lipids. Predicted reduction in diabetes
risk was estimated from the effects of weight reduction
in the lifestyle arm of the US Diabetes Prevention
Program, where risk reduced by 10% for each percent-
age point of weight loss at 6 months.27 There is evidence
that the relationship is linear9 28 29 and that even
modest weight reduction can reduce the risk of develop-
ing diabetes.30 An ongoing association between initial
weight loss and reduced diabetes risk is supported by
several clinical trials.27 31 32
CVD risk was calculated for participants without pre-
existing CVD at recruitment using a modiﬁed
Framingham risk equation including age, total serum
cholesterol, HDL-cholesterol, sex, systolic BP, smoking
status, and diabetes status (all participants non-diabetic
at baseline).33
Sample size and power calculation
The power calculation was based on our previous
study,12 and provided sufﬁcient power to assess the effect
on weight, waist circumference, FPG, HDL-cholesterol,
and diastolic BP. The RCT was designed to detect a 0.23
effect size on diastolic BP with 80% power and 5% sig-
niﬁcance level. Diastolic BP as an outcome measure was
predicted to need the largest sample size, requiring 398
participants in each arm, allowing for 25% attrition.18
Owing to slow accrual of participants, combined with
MDPS ﬁxed-term funding, 342 were ultimately rando-
mized into the study—177 intervention and 165 control.
The revised effect size for diastolic BP that could be
detected with a two-sided, two-sample t test at the 5%
signiﬁcance level and 80% power was 0.30.
Data analysis
Analyses of primary end points were performed using
SPSS V.20 and independently veriﬁed in GenStat
Release V.16.1. Participants’ baseline characteristics are
presented as summary measures. Analyses were carried
out for all participants randomized to the study (inten-
tion to treat (ITT) set) and for the per protocol set
(PPS), sometimes referred to as the modiﬁed ITT ana-
lysis set; the subset of participants in the full analysis set
without major protocol deviations. Such protocol devia-
tions were determined independently of and prior to
the unblinding of the trial statistician. These included
postbaseline assessments beyond the speciﬁed time
window (n=2); randomized to control group but
attended a Life! group or randomized to intervention
and household member attended a Life! group (n=2);
medical conditions potentially causing large weight loss
or gain (colon resection, recent mastectomy, removal of
skin ﬂaps) (n=3); sharing residence with someone ran-
domized to a different arm (n=12); attending individual
session only (n=4); and failure to attend any of the inter-
vention sessions (n=21).
Mixed model analyses of continuous scale end points
used the residual maximum likelihood method to cope
with missing values. Signiﬁcance of the F-test for the
group by time interaction is reported as well as t tests for
the within-group changes over time and the
between-group differences at each time. The proportion
of participants in each group known to have achieved
each of the dietary and physical activity goals at T1 and
T3 was calculated, and the method of generalized esti-
mating equations was used to ﬁt models to enable group
by time interactions to be tested (Wald χ2 test). The
body weight goal (≥5% reduction at 12 months) was
assessed using a two-sample binomial test to compare
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the proportions in each group. The number of goals
achieved by individuals at 12 months was assessed using
a mixed model analysis. Sensitivity analyses, in which
missing assessments were deemed to indicate unmet
goals, were conducted for each goal and also for the
combined score. Unless otherwise stated, statistical tests
were conducted at the 5% signiﬁcance level without
adjustments for multiplicity of either end points or
comparisons.
Participants
In total, 2616 individuals were screened for eligibility,
with 1067 having AUSDRISK score ≥15. For various
reasons, 725 people declined to participate. The ITT
analysis set consisted of the remaining 342 participants
—177 intervention and 165 control arm (see online sup-
plementary ﬁle 2—CONSORT diagram). Major protocol
deviations resulted in exclusion of further 44 partici-
pants. The PPS consisted of 298 participants—143 inter-
vention and 155 control arm.
Ethics
Deakin University Human Research Ethics Committee
granted approval—project code 2009-066. MDPS was
registered with the Australian New Zealand Clinical Trial
registry: ACTRN12609000507280.
RESULTS
Control and intervention arms had similar character-
istics at baseline (table 1). Overall mean age was 65 years
with 38% men. At baseline, 290 (84.8%) participants in
the ITT had a FPG ≤5.6 mmol/L and 52 (15.2%) parti-
cipants had a FPG 5.7–6.9 mmol/L (impaired fasting
glucose). Similarly 281 (82.4%) participants in the ITT
had a 2 h OGTT glucose ≤7.8 mmol/L and n=60
(17.6%) had a 2 h OGTT glucose 7.9–11.0 mmol/L
(impaired glucose tolerance).
Table 2 presents the main outcome measure results of
the PPS and ITT data sets. PPS results were considered
more informative for the reasons outlined in the discus-
sion, hence only the PPS results are given here.
At 12 months in the PPS, the intervention group
mean weight loss was 0.84 kg but controls gained 0.29 kg
(mean difference 1.13 kg; p=0.016). Similarly the inter-
vention group mean waist circumference decreased by
0.90 cm but controls increased by 0.45 cm (mean differ-
ence 1.35 cm; p=0.044). This 0.96% weight reduction
predicts a 9.6% diabetes risk reduction. The interven-
tion group reduced systolic BP by 7.3 mm Hg and con-
trols by 2.1 mm Hg (mean difference 5.2 mm Hg;
p=0.028). A similar effect was seen in diastolic BP. The
intervention group reduced diastolic BP by 4.9 mm Hg
and controls by 1.7 mm Hg (mean difference
3.2 mm Hg; p=0.030). There were no signiﬁcant time–
arm interactions for FPG, OGTT 2 h glucose, total chol-
esterol, LDL-cholesterol, HDL-cholesterol, or
triglycerides.
In the analysis of the PPS for patients without estab-
lished CVD, average 5-year Framingham absolute CVD
risk decreased in the intervention group from 9.72% to
8.75% (p=0.002, 10.4% relative risk reduction), and
increased in controls from 8.35% to 8.46% (p=0.712,
1.3% relative risk increase) resulting in a net effect of
−1.08% points of absolute risk. The interaction between
time and study arm was statistically signiﬁcant (p=0.013).
Using the PPS, the 3 month intensive intervention
phase showed statistically signiﬁcant reductions in
weight, waist, systolic and diastolic BP, and Framingham
5-year absolute risk compared with baseline for interven-
tion participants. There was also a statistically signiﬁcant
increase in HDL-cholesterol (see online supplementary
ﬁle 3). Between 3 and 12 months, diastolic BP was
reduced further and there were slight but non-
signiﬁcant increases in weight, systolic BP, and
Framingham 5-year absolute risk. A signiﬁcant increase
of 1 cm in waist circumference occurred between 3 and
12 months.
In the PPS, the proportion of participants meeting the
ﬁber intake goal increased from 20% (baseline) to 33%
(12 months) in the intervention arm, but there was no
Figure 1 Structure of the
Melbourne Diabetes Prevention
Study (MDPS).
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Table 1 Baseline characteristics of control participants, intervention participants, and all participants in the Melbourne
Diabetes Prevention Study
Control (n=165) Intervention (n=177) All participants (n=342)
Gender (men) 61 (37.0%) 68 (38.4%) 129 (37.7%)
Age (years)
N 165 177 342
Mean (SD) 65.0 (6.7) 65.1 (6.2) 65.0 (6.4)
Median 66.0 66.0 66.0
Age (%)
0–49 1 (0.6) – 1 (0.3)
50–54 15 (9.1) 10 (5.6) 25 (7.3)
55–59 18 (10.9) 26 (14.7) 44 (12.9)
60–64 34 (20.6) 41 (23.2) 75 (21.9)
65–69 51 (30.9) 46 (26.0) 97 (28.4)
70–74 35 (21.2) 50 (28.2) 85 (24.9)
75–80 11 (6.7) 4 (2.3) 15 (4.4)
AUSDRISK
N 165 177 342
Mean (SD) 18.2 (3.2) 18.7 (3.5) 18.5 (3.3)
15–19 (%) 121 (73.3) 118 (66.7) 239 (69.9)
≥20 (%) 44 (26.6) 59 (33.3) 103 (30.1)
Framingham 5-year CVD risk
N 152 142 294
Mean (SD) 8.3 (6.0) 9.4 (5.9) 8.8 (6.0)
Median 6.8 8.2 7.2
Waist (cm)
N 163 177 340
Mean (SD) 102.5 (12.7) 101.7 (12.2) 102.1 (12.4)
Median 102.0 101.8 101.90
Waist (%)
<80 5 (3.1) 9 (5.1) 14 (4.1)
80 to <90 21 (12.9) 23 (13.0) 44 (12.9)
90 to <100 43 (26.4) 45 (25.4) 88 (25.9)
100 to <110 51 (31.3) 54 (30.5) 105 (30.9)
110 to <120 26 (16.0) 32 (18.1) 58 (17.1)
>120 17 (10.4) 14 (7.9) 31 (9.1)
BMI (kg/m2)
N 163 177 340
Mean (SD) 31.34 (5.22) 31.16 (4.97) 31.25 (5.08)
<20 (%) 1 (0.6) 0 (0) 1 (0.3)
20 to <25 (%) 11 (6.7) 14 (7.9) 25 (7.4)
25 to <30 (%) 60 (36.8) 66 (37.3) 126 (37.1)
>30 (%) 91 (55.8) 97 (54.8) 188 (55.3)
Weight (kg)
N 163 177 340
Mean (SD) 87.4 (16.1) 86.5 (15.3) 87.0 (15.7)
Education (years)
N 160 172 332
Mean (SD) 12.68 (3.09) 12.98 (3.88) 12.83 (3.51)
Primary (%) 49 (30.6) 55 (32.0) 104 (31.3)
Secondary (%) 45 (28.1) 56 (32.6) 101 (30.4)
Tertiary (%) 66 (41.3) 61 (35.5) 127 (38.3)
Income level
N 163 175 338
High (%) 87 (52.73) 89 (50.28) 176 (51.46)
Medium (%) 48 (29.09) 62 (35.03) 110 (32.16)
Low (%) 28 (16.97) 24 (13.56) 52 (15.20)
Smoking status
N 165 176 341
Continued
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change in the control arm (p=0.028). A greater percent-
age of participants in the intervention group than in the
control group achieved the 5% weight reduction goal
(15% vs 8%; p=0.026). The total number of goals achieved
at the conclusion of the study in the intervention group
was higher than in the control group (1.26 vs 0.94;
p=0.003). A similar conclusion held when missing goal
assessments were assumed to be unmet goals (table 3).
CONCLUSIONS
This is the ﬁrst report of an evaluation for a scaled-up
diabetes prevention programme using an RCT. The
MDPS was an effectiveness trial linked to the statewide,
translational diabetes prevention programme Life! in
Victoria, Australia. In the PPS analysis after 12 months,
MDPS showed signiﬁcant improvements in weight, waist,
BP, and CVD risk in the intervention group compared
with usual care. Diabetes risk was also reduced. A statis-
tically signiﬁcant CVD risk reduction between baseline
and 12 months was shown in the intervention group
with no change in the control group. The intervention
group CVD risk reduction resulted mainly from a consid-
erable BP reduction, which was not explained by any
single factor, such as weight loss, physical activity, or
medication changes, between baseline and 12 months.
The improvement in BP is likely to be multifactorial
with exercise, weight loss, reduced salt intake, and medi-
cation all having contributory effects.
MDPS showed a smaller intervention effect compared
with some other trials, possibly because lower baseline
risk meant there was less scope for improvement in
health measures.6 12 A similar effect was seen in FIN
D2D which was a real-world scaled-up programme run
in Finnish primary healthcare.9 However, even a modest
1 kg weight reduction can reduce diabetes risk by
16%.32
Life! is the second scaled-up diabetes prevention pro-
gramme to be reported, after the FIN D2D programme.
Several randomized efﬁcacy trials demonstrated that life-
style modiﬁcation interventions are effective in reducing
T2DM risk.2–4 Many translational ‘real-world’ diabetes
prevention programmes have also demonstrated positive
results, but they were all small scale.6 Once high-risk
individuals attend the interventions, and especially if the
intervention dose is large enough, they beneﬁt remark-
ably from lifestyle modiﬁcation.6 Furthermore, partici-
pants from all socioeconomic groups seem to beneﬁt
equally.34 What has been missing is the rigor of an RCT,
in real-world, scaled-up settings to measure impact.
Public health interventions and ITT analysis
Although some would see ITT as the gold standard for
reporting real-world diabetes prevention programmes,
not all studies included in the recent systematic review
reported ITT.6 In MDPS, a single intervention partici-
pant who gained 20 kg contributed to the non-
signiﬁcant effect in the ITT analysis. If he was excluded
from analysis, weight reduction changes from p=0.079 to
0.026. The PPS analysis excluded this participant (prior
to statistician unblinding) because he did not attend any
intervention sessions. The PPS analysis relates to an idea-
lized situation and demonstrates what the beneﬁts can
be for willing participants. Health services planning is
based on those who are prepared to participate in an
intervention. By presenting both ITT and PPS data, we
aim to show a fuller picture.
Table 1 Continued
Control (n=165) Intervention (n=177) All participants (n=342)
Non-smoker (%) 155 (93.9) 162 (92.0) 317 (93.0)
Current smoker (%) 10 (6.1) 14 (8.0) 24 (7.0)
Work status
N 157 166 323
Fulltime employed (%) 13 (7.9) 12 (6.9) 25 (7.4)
Part-time or casual employed (%) 30 (18.2) 34 (19.4) 64 (18.8)
Unemployed and seeking work (%) 1 (0.6) 3 (1.7) 4 (1.2)
Home duties (%) 19 (11.5) 13 (7.4) 32 (9.4)
Retired/pensioner (%) 90 (54.5) 103 (58.9) 193 (56.8)
Full-time carer (%) 4 (2.4) 1 (0.6) 5 (1.5)
HADS-A
N 164 175 339
Normal (<7) (%) 54 (32.9) 60 (34.3) 114 (33.6)
Mild anxiety (8–10) (%) 82 (50.0) 79 (45.1) 161 (47.5)
Moderate-severe anxiety (≥11) (%) 28 (17.1) 36 (20.6) 64 (18.9)
HADS-D
N 164 174 338
Normal (<7) (%) 26 (15.9) 36 (20.7) 62 (18.3)
Mild depression (8–10) (%) 128 (78.0) 133 (76.4) 261 (77.2)
Moderate-severe depression (≥11) (%) 10 (6.1) 5 (2.9) 15 (4.4)
BMI, body mass index; CVD, cardiovascular disease; HADS, hospital anxiety and depression score.
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Table 2 Two-way table of predicted means (SEM) of time and group using ITT and the PPS
Control Intervention Difference p Value
PPS
Weight (kg)
Baseline 87.81 (1.36) 87.52 (1.36) −0.29 0.880
12 months 88.10 (1.36) 86.68 (1.36) −1.42 0.461
Difference 0.29 −0.84 −1.13
p Value 0.378 0.012 0.016*
Waist (cm)
Baseline 102.55 (1.07) 102.39 (1.07) −0.16 0.914
12 months 102.99 (1.07) 101.48 (1.07) −1.51 0.318
Difference 0.45 −0.90 −1.35
p Value 0.345 0.057 0.044*
FPG (mmol/L)
Baseline 5.09 (0.05) 5.16 (0.05) 0.06 0.381
12 months 5.15 (0.05) 5.22 (0.05) 0.07 0.321
Difference 0.06 0.07 0.01
p Value 0.231 0.170 0.903*
OGTT 2 h glucose
Baseline 6.19 (0.16) 6.19 (0.16) 0.00 0.993
12 months 6.11 (0.16) 6.06 (0.16) −0.05 0.822
Difference −0.08 −0.13 −0.05
p Value 0.566 0.347 0.802*
Systolic (mm Hg)
Baseline 139.89 (1.51) 144.14 (1.51) 4.25 0.049
12 months 137.75 (1.51) 136.83 (1.51) −0.92 0.666
Difference −2.14 −7.31 −5.17
p Value 0.198 <0.001 0.028*
Diastolic (mm Hg)
Baseline 80.71 (0.98) 81.39 (0.98) 0.68 0.623
12 months 79.03 (0.98) 76.47 (0.98) −2.56 0.065
Difference −1.68 −4.92 −3.24
p Value 0.111 <0.001 0.030*
Total cholesterol (mmol/L)
Baseline 5.22 (0.09) 5.19 (0.09) −0.03 0.813
12 months 5.26 (0.09) 5.08 (0.09) −0.18 0.172
Difference 0.04 −0.11 −0.15
p Value 0.581 0.140 0.152*
Triglycerides (mmol/L)
Baseline 1.44 (0.05) 1.36 (0.05) −0.08 0.277
12 months 1.58 (0.05) 1.44 (0.05) −0.14 0.054
Difference 0.15 0.08 −0.06
p Value <0.001 0.037 0.263*
LDL-cholesterol (mmol/L)
Baseline 3.01 (0.08) 3.08 (0.08) 0.07 0.571
12 months 3.00 (0.08) 2.90 (0.08) −0.10 0.384
Difference −0.01 −0.18 −0.17
p Value 0.881 0.008 0.075*
HDL-cholesterol (mmol/L)
Baseline 1.52 (0.04) 1.49 (0.04) −0.03 0.596
12 months 1.53 (0.04) 1.52 (0.04) −0.01 0.856
Difference 0.01 0.03 0.02
p Value 0.498 0.081 0.448*
Framingham 5-year CVD risk (%)
Baseline 8.35 (0.54) 9.72 (0.54) 1.37 0.075
12 months 8.46 (0.54) 8.75 (0.54) 0.29 0.704
Difference 0.11 −0.97 −1.08
p Value 0.712 0.002 0.013*
ITT
Weight (kg)
Continued
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Table 2 Continued
Control Intervention Difference p Value
Baseline 87.35 (1.24) 86.53 (1.20) −0.82 0.636
12 months 87.61 (1.25) 85.95 (1.20) −1.67 0.337
Difference 0.26 −0.59 −0.85
p Value 0.451 0.079 0.079*
Waist (cm)
Baseline 102.46 (0.97) 101.72 (0.94) −0.74 0.584
12 months 102.87 (0.99) 101.13 (0.95) −1.74 0.205
Difference 0.41 −0.59 −1.00
p Value 0.379 0.187 0.122*
FPG (mmol/L)
Baseline 5.07 (0.05) 5.14 (0.04) 0.06 0.328
12 months 5.14 (0.05) 5.19 (0.05) 0.04 0.514
Difference 0.07 0.05 0.02
p Value 0.122 0.236 0.763*
OGTT 2 h glucose (mmol/L)
Baseline 6.18 (0.15) 6.19 (0.14) 0.00 0.983
12 months 6.12 (0.15) 5.97 (0.15) −0.16 0.452
Difference −0.06 −0.22 −0.16
p Value 0.668 0.083 0.377*
Systolic BP (mm Hg)
Baseline 140.23 (1.39) 143.00 (1.34) 2.77 0.152
12 months 137.57 (1.45) 136.34 (1.40) −1.22 0.544
Difference −2.66 −6.65 −3.99
p Value 0.091 <0.001 0.068*
Diastolic BP (mm Hg)
Baseline 80.89 (0.90) 81.33 (0.87) 0.44 0.725
12 months 78.65 (0.94) 76.32 (0.91) −2.33 0.076
Difference −2.24 −5.01 −2.77
p Value 0.025 <0.001 0.046*
Total cholesterol (mmol/L)
Baseline 5.23 (0.09) 5.21 (0.09) −0.02 0.877
12 months 5.28 (0.09) 5.14 (0.09) −0.14 0.263
Difference 0.05 −0.07 −0.12
p Value 0.452 0.308 0.212*
Triglycerides (mmol/L)
Baseline 1.43 (0.07) 1.49 (0.07) 0.06 0.506
12 months 1.56 (0.07) 1.53 (0.07) −0.03 0.741
Difference 0.13 0.03 0.10
p Value 0.004 0.436 0.125*
LDL-cholesterol (mmol/L)
Baseline 3.02 (0.08) 3.10 (0.07) 0.07 0.486
12 months 3.03 (0.08) 2.94 (0.08) −0.09 0.421
Difference 0.01 −0.16 −0.17
p Value 0.927 0.011 0.068*
HDL-cholesterol (mmol/L)
Baseline 1.52 (0.04) 1.52 (0.04) 0.00 0.951
12 months 1.53 (0.04) 1.55 (0.04) 0.02 0.760
Difference 0.01 0.03 0.02
p Value 0.601 0.053 0.336*
Framingham 5-year CVD risk (%)
Baseline 8.20 (0.46) 9.35 (0.44) 1.15 0.072
12 months 8.28 (0.45) 8.40 (0.44) 0.12 0.851
Difference 0.08 −0.95 −1.03
p Value 0.782 0.001 0.011*
*p Value for the F-test of the time by group interaction.
BP, blood pressure; CVD, cardiovascular disease; FPG, fasting plasma glucose; HDL, high-density lipoprotein; ITT, intention to treat; LDL,
low-density lipoprotein; OGTT, oral glucose tolerance test; PPS, per protocol set.
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Programme drift
A major concern about real-world diabetes prevention
programmes is the extent of beneﬁt delivered over
extended time periods, particularly important given the
long-term payback on investment. Programme drift
denotes deviation from protocol resulting in a reduced
Table 3 Proportions (%) of participants meeting the goals of the Life! programme at baseline and 12 months, and total
number of goals achieved at 12 months for PPS and ITT
Control Intervention p Value
PPS
No more than 30% energy from fat
T1 18/153 (11.76%) 11/143 (7.69%) 0.242
T3 9/136 (6.62%) 14/138 (10.14%) 0.282
p Value 0.065 0.399 0.056*
No more than 10% energy from saturated fat
T1 14/153 (9.15%) 6/143 (4.20%) 0.098
T3 5/136 (3.68%) 8/138 (5.80%) 0.400
p Value 0.018 0.454 0.028*
At least 15 g/1000 kcal fiber intake
T1 33/153 (21.57%) 29/143 (20.28%) 0.785
T3 30/136 (22.06%) 46/138 (33.33%) 0.039
p Value 0.945 0.001 0.028*
At least 30 min/day moderate intensity
T1 75/145 (51.72%) 85/137 (62.04%) 0.074
T3 71/133 (53.38%) 88/134 (65.67%) 0.039
p Value 0.729 0.456 0.757*
At least a 5% reduction in body weight
Goal 5 (weight loss) 8/133 (6.0%) 19/134 (14.1%) 0.027
Mean total number of goals achieved†
Control (n=129) Intervention (n=133)
0.94 1.29 0.003
Mean total number of goals achieved‡
Control (n=154) Intervention (n=143)
0.79 1.22 <0.001
ITT
No more than 30% energy from fat
T1 21/162 (13.0%) 15/177 (8.5%) 0.185
T3 12/146 (8.2%) 15/162 (9.3%) 0.702
p Value 0.066 0.785 0.153*
No more than 10% energy from saturated fat
T1 16/162 (9.9%) 8/177 (4.5%) 0.061
T3 7/146 (4.8%) 9/162 (5.6%) 0.777
p Value 0.029 0.668 0.079*
At least 15 g/1000 kcal fiber intake
T1 34/162 (21.0%) 36/177 (20.3%) 0.894
T3 31/146 (21.2%) 52/162 (32.1%) 0.034
p Value 0.971 0.002 0.035*
At least 30 min/day moderate intensity
T1 80/154 (52.0%) 106/169 (62.7%) 0.041
T3 75/142 (52.8%) 98/156 (62.8%) 0.079
p Value 0.861 0.912 0.840*
At least a 5% reduction in body weight
Goal 5 (weight loss) 11/143 (7.7%) 24/157 (15.3%) 0.041
Mean total number of goals achieved†
Control (n=139) Intervention (n=154)
0.97 1.25 0.011
Mean total number of goals achieved‡
Control (n=165) Intervention (n=177)
0.82 1.12 0.005
*p Value for the Wald χ2 test of the time by group interaction.
†Participants with one or more missing data excluded.
‡Missing data replaced with non-achievement of goal.
IIT, intention to treat; PPS, per protocol set.
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effect, and it is potentially an important cause of attenu-
ated effect.17
In common with diabetes prevention programmes
generally, recruiting difﬁculties for MDPS were a chal-
lenge from the outset.35 Most participants were recruited
during a brief contact in pharmacies and followed up by
the study nurses. The recorded reasons for not proceed-
ing to baseline testing were: no longer being interested,
meeting exclusion criteria, AUSDRISK being below
threshold on checking, living too far from the interven-
tion, or becoming ill. After baseline testing, MDPS attri-
tion rate was low mainly because the same nurse was
involved in all participant contacts through to the ﬁnal
testing, multiple contact methods were used and the
nurses were persistent. Similarly, recruitment into Life!
was initially challenging and led to ongoing modiﬁca-
tions of the programme to respond to that challenge.10
This raises issues about motivating high-risk individuals
to participate in such programmes, in order for the pro-
grammes to improve their effect, and ensure their
future sustainability. Another example of programme
drift in MDPS (and Life!) was that intervention partici-
pant weight and waist circumference did not continue
to reduce between 3 and 12 months (see online supple-
mentary ﬁle 3), unlike in the original GGT DPP.9 The
MDPS intervention dose was lower in terms of number
of sessions included and time allocated to self-
monitoring tools feedback, for example, food and phys-
ical activity diaries.12 This reduction potentially
decreased the level of social support and intervention
intensity experienced by participants.36 Providing indivi-
dualized risk feedback is important and more likely to
result in behavior change than generalized feedback.37
A recent systematic review described the importance of
intervention intensity and ﬁdelity for achieving positive
outcomes.6
Voltage drop
Voltage drop denotes the reduced beneﬁts of diabetes
prevention programmes when they move from efﬁcacy
trials to the real world. Voltage drop in MDPS (and
Life!) might largely be explained by participant screen-
ing using AUSDRISK. MDPS baseline weight, waist,
lipids, and glucose measures were all noticeably lower
than in GGT DPP,12 and MDPS participants were
10 years older. Relatively low baseline diabetes risk might
also explain the absence of changes in glucose mea-
sures. Participants at low risk would have become aware
of this fact during their ﬁrst session, which may have
reduced their motivation for lifestyle modiﬁcation.
Mean AUSDRISK score for MDPS participants was 18.5
corresponding to a risk of one in seven developing
T2DM. In our earlier GGT DPP, mean FINDRISC score
of participants was 15.7 corresponding to a higher risk
of one in three.12 These results raise the question about
which entry score to use for identifying high-risk indivi-
duals for admission into interventions. We note in our
cohort that BP and cholesterol were lower than the GGT
DPP12 and Finnish DPS4 at baseline. This is the ﬁrst
report comparing AUSDRISK’s performance in a life-
style modiﬁcation intervention trial. AUSDRISK entry
score was established by the Council of Australian
Governments for use by all state and federally funded
programmes, including the Life! programme, with a
score ≥15 indicating high risk of developing diabetes (1
in 7 risk). Subsequently eligibility for Life! changed to a
score ≥12 which is equal to a 1 in 14 risk of developing
diabetes. High BMI is a signiﬁcant predictor of T2DM,
but BMI is not included in AUSDRISK. FINDRISC
includes both BMI and waist circumference.
Furthermore, as AUSDRISK is heavily loaded for age,
male gender, and other non-modiﬁable risk factors,
even AUSDRISK score ≥20 can still result in participants
entering programmes with only non-modiﬁable risk
factors detected.
Screening into diabetes prevention programmes in
the real world usually includes a glucose metabolism
indicator as an entry criterion.6 FPG has been shown to
strongly improve the performance of risk prediction
models based on non-invasive measures (routinely col-
lected data or questionnaire data).38 Based on this evi-
dence and our ﬁndings, we recommend that a glucose
metabolism measure be used in conjunction with a dia-
betes risk score when screening for high-risk individuals
to enter into diabetes prevention programmes. The
obligatory use of AUSDRISK is an example of voltage
drop caused by real world, an unintended adverse con-
sequence of government policy.
Consequently, there are lessons about hazards of devel-
oping new risk assessment tools rather than using the
internationally well-established FINDRISC.39 In the only
other reported scaled-up diabetes prevention pro-
gramme, FIN D2D, the entry criterion was set at a
FINDRISC score ≥159 which is equivalent to 20 on the
AUSDRISK. Rather than overwhelm health services, the
Finnish government decided to only take those at highest
risk, as approximately 30% of the population aged
50 years or over is at moderate-to-high risk of developing
T2DM.40 The current AUSDRISK score for entry into dia-
betes prevention programmes needs to be revised.
Strengths, limitations and implications
Using an RCT with well-matched intervention and
control groups, we critically investigated a real-world,
scaled-up implementation of a diabetes prevention pro-
gramme in order to learn more about effectiveness. We
have provided recommendations on how the Life! pro-
gramme can be improved. The main difﬁculty of the
MDPS appears to relate to recruitment being consider-
ably less than originally intended. Potential participants
were more willing to be recruited to the Life! pro-
gramme or be recommended to the Life! programme by
their GPs than to take the perceived risk of being in the
control group of the RCT. Additionally, the MDPS parti-
cipants were older, with a higher proportion retired, and
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having smaller waist circumferences than those in Life!,
limiting the effect the intervention might have.
Challenges during the enrolment phase and funding
constraints resulted in the recruitment of 342 partici-
pants (177 intervention and 165 control) out of an
initial target of 796 (398 per arm). With the reduced
numbers, the trial was still powered to detect
small-to-moderate effect sizes for diastolic BP, 2 h OGTT,
total cholesterol, LDL, weight, and waist circumference.
At this sample size, the trial was underpowered to detect
differences in FPG, triglycerides, systolic BP, and diastolic
BP—noting that the two BP measures were signiﬁcant
when testing the group by time interaction.
This study’s strength was the rigorous methodology for
MDPS data collection compared with the data collected
in Life! For example, MDPS weight and waist circumfer-
ence were performed by study nurses who used strict
protocols. In Life! facilitators perform the measures with
no external veriﬁcation of data accuracy. These strengths
and limitations may explain much of the difference in
effect size between MDPS and Life!10
Building a sustainable health promotion programme
requires long-term ﬁnancing, workforce training, super-
vision, and organizational support. The beneﬁts of
engaging in ongoing development, evaluation, and
reﬁnement of programmes should show as increased
effects, improved quality, or both.17 Based on this study,
the Life! programme could apply quality improvement
strategies to the intervention to achieve better impact
and sustainability.
This study highlights the need to identify and recruit
participants more likely to beneﬁt from lifestyle modiﬁ-
cation programmes. When scaling-up diabetes preven-
tion programmes in the real world, maintaining ﬁdelity
to the original components is an essential requirement,
along with the need for ongoing accurate data collection
to facilitate quality improvement aimed at enhancing
sustainability and effect.
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